Skip to content

Study · Randomized controlled trial · n = 58 · 2013

6 results

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.

Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, Seon HJ, Kim KS

Arteriosclerosis, thrombosis, and vascular biology18 Jul 2013Cited by 183 (Europe PMC)

PMID23868944 (opens in a new tab)DOI10.1161/atvbaha.113.301586 (opens in a new tab)PepBankPUB-23868944
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with myocardial infarction, exenatide reduced creatine kinase-MB release compared with controls.

    In plain wordsIn patients with a heart attack, exenatide reduced creatine kinase-MB release compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCreatine kinase-MB release
    Study

    n = 58

    Comparator
    Placebo saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The releases of creatine kinase-MB and troponin I were significantly reduced in the exenatide group.
    1 context sentence
    Summary · context
    Fifty-eight patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0 were enrolled in the study and randomly assigned to receive either exenatide or placebo (saline) subcutaneously.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with myocardial infarction, exenatide reduced troponin I release compared with controls.

    In plain wordsIn patients with a heart attack, exenatide reduced troponin I release compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTroponin I release
    Study

    n = 58

    Comparator
    Placebo saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The releases of creatine kinase-MB and troponin I were significantly reduced in the exenatide group.
    1 context sentence
    Summary · context
    Fifty-eight patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0 were enrolled in the study and randomly assigned to receive either exenatide or placebo (saline) subcutaneously.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with myocardial infarction, delayed hyperenhancement mass was 12.8±11.7 g with exenatide versus 26.4±11.6 g in controls.

    In plain wordsIn patients with a heart attack, exenatide reduced the mass of damaged heart tissue compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseDelayed hyperenhancement mass
    Study

    n = 58

    Comparator
    Placebo saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Delayed hyperenhancement mass
    12.8 g
    exenatide
    Delayed hyperenhancement mass
    26.4 g
    control

    Source sentences

    Summary
    In 58 patients evaluated with cardiac magnetic resonance, the absolute mass of delayed hyperenhancement was significantly reduced in the exenatide group as compared with the control group (12.8±11.7 versus 26.4±11.6 g; P<0.01).
    2 context sentences
    Summary · context
    Infarct size was assessed by measuring the release of creatine kinase-MB and troponin I during 72 hours and by performing cardiac magnetic resonance imaging at 1 month after infarction.
    Summary · context
    Fifty-eight patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0 were enrolled in the study and randomly assigned to receive either exenatide or placebo (saline) subcutaneously.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with myocardial infarction, exenatide reduced E/E' compared with controls at 6 months.

    In plain wordsIn patients with a heart attack, exenatide lowered the E/E' heart function measure compared with controls at 6 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseE/E' at follow-up
    Study

    n = 58

    Comparator
    Placebo saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    At 6 months, the exenatide group showed a significantly lower value of E/E' with improved strain parameters.
    1 context sentence
    Summary · context
    Fifty-eight patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0 were enrolled in the study and randomly assigned to receive either exenatide or placebo (saline) subcutaneously.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with myocardial infarction, exenatide improved strain parameters at 6 months compared with controls.

    In plain wordsIn patients with a heart attack, exenatide improved heart strain measures compared with controls at 6 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedStrain parameters
    Study

    n = 58

    Comparator
    Placebo saline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    At 6 months, the exenatide group showed a significantly lower value of E/E' with improved strain parameters.
    1 context sentence
    Summary · context
    Fifty-eight patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0 were enrolled in the study and randomly assigned to receive either exenatide or placebo (saline) subcutaneously.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with myocardial infarction, no significant adverse effects of exenatide were detected.

    In plain wordsIn patients with a heart attack, researchers detected no significant adverse effects of exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSignificant adverse effects
    Study

    n = 58

    Comparator
    Placebo saline
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    No significant adverse effects of exenatide administration were detected.
    1 context sentence
    Summary · context
    Fifty-eight patients with ST-segment-elevation myocardial infarction and thrombolysis in myocardial infarction flow 0 were enrolled in the study and randomly assigned to receive either exenatide or placebo (saline) subcutaneously.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02602600

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Eva Prescottn = 3319 Nov 2015 to 18 Apr 2017

Microvascular Angina

Trial pageClinicalTrials.govUpdated 11 Jul 2018
CompletedPhase 4NCT01580514

Myocardial Protection of Exenatide in AMI

Kyunghee University Medical Centern = 127Sept 2009 to Aug 2011

Myocardial Infarction

Trial pageClinicalTrials.govUpdated 19 Apr 2012

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.